Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
Status:
Recruiting
Trial end date:
2027-09-27
Target enrollment:
Participant gender:
Summary
Patients with oligometastatic squamous cell carcinoma were enrolled and randomly assigned to
receive either PD-1 inhibitor +/- chemotherapy combined with local therapy or PD-1 inhibitor
+/- chemotherapy alone.
The primary end point was progression-free survival (PFS). The secondary end points included
overall survival, side effects and local control.